Stella Pharma Corporation (4888.T)
JPY 397.0
(-1.0%)
JPY 397.0
(-1.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 269.49 Million JPY | 17.65% |
| 2022 | 229.06 Million JPY | 128.85% |
| 2021 | 100.09 Million JPY | -51.4% |
| 2020 | 205.96 Million JPY | 0.0% |
| 2019 | - JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 61.59 Million JPY | -11.11% |
| 2023 Q2 | 92.39 Million JPY | 50.0% |
| 2023 FY | 269.49 Million JPY | 17.65% |
| 2023 Q4 | 69.29 Million JPY | 50.0% |
| 2023 Q3 | 46.19 Million JPY | -50.0% |
| 2023 Q1 | 61.59 Million JPY | 14.29% |
| 2022 Q3 | 82.77 Million JPY | 79.16% |
| 2022 FY | 229.06 Million JPY | 128.85% |
| 2022 Q4 | 53.89 Million JPY | -34.88% |
| 2022 Q2 | 46.19 Million JPY | 0.0% |
| 2021 FY | 100.09 Million JPY | -51.4% |
| 2020 FY | 205.96 Million JPY | 0.0% |
| 2019 FY | - JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 94.35% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | -138.644% |
| GNI Group Ltd. | 26.01 Billion JPY | 98.964% |
| Linical Co., Ltd. | 12.3 Billion JPY | 97.81% |
| Trans Genic Inc. | 13.08 Billion JPY | 97.94% |
| MEDINET Co., Ltd. | 661.54 Million JPY | 59.263% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 94.776% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | 82.729% |
| AnGes, Inc. | 152.98 Million JPY | -76.155% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | 55.83% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 97.889% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | 67.002% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | -98.875% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | 83.425% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | 37.088% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | 85.825% |
| Chiome Bioscience Inc. | 682.46 Million JPY | 60.512% |
| Kidswell Bio Corporation | 2.43 Billion JPY | 88.915% |
| PeptiDream Inc. | 28.71 Billion JPY | 99.061% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | -327.506% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | -122.72% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -374193.056% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | -575.636% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | 94.025% |
| FunPep Company Limited | 530 Thousand JPY | -50747.358% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -289.157% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | 14.938% |
| Cuorips Inc. | 23.1 Million JPY | -1066.527% |
| K Pharma,Inc. | 1 Billion JPY | 73.051% |
| Takara Bio Inc. | 43.5 Billion JPY | 99.381% |
| ReproCELL Incorporated | 2.42 Billion JPY | 88.895% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | 84.289% |
| StemCell Institute Inc. | 2.48 Billion JPY | 89.139% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 89.281% |
| CellSeed Inc. | 190.13 Million JPY | -41.737% |